In recent years, continuous intraperitoneal insulin infusion (CIPII) has become a valid therapeutic option to achieve good glycemic control for patients with unstable type 1 diabetes and subcutaneous insulin resistance, mainly due to the absorption of insulin through the portal venous system. Here, INS is linked to Insulin resistance.